George M Rodgers
Overview
Explore the profile of George M Rodgers including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
93
Citations
909
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
2.
Lim M, Sivaloganathan V, Rodgers G, Simonsen S
Thromb Res
. 2025 Jan;
246():109253.
PMID: 39787817
Background: When using electronic health records (EHRs) to conduct population-based studies on inherited bleeding disorders (IBDs), using diagnosis codes alone results in a high number of false positive identifications. Objective:...
3.
4.
Rodgers G
Expert Rev Hematol
. 2024 Jul;
17(8):505-514.
PMID: 38949158
Introduction: Numerous clinical trials affirm the efficacy and safety of IV iron to treat cancer-related anemia (CRA). Nonetheless, evaluation and treatment of CRA remains suboptimal. Areas Covered: This review summarizes...
5.
Lim M, Rodgers G, Branch D, Simonsen S
Haemophilia
. 2024 Feb;
30(2):470-477.
PMID: 38343098
Introduction: Guidelines on the management of pregnant individuals with von Willebrand disease (VWD) at the time of delivery recommend that von Willebrand factor (VWF) and factor VIII:C (FVIII:C) levels be...
6.
Rodgers G, Mahajerin A
Clin Appl Thromb Hemost
. 2023 Oct;
29:10760296231205279.
PMID: 37822179
Antithrombin (AT) is a natural anticoagulant pivotal in inactivating serine protease enzymes in the coagulation cascade, making it a potent inhibitor of blood clot formation. AT also possesses anti-inflammatory properties...
7.
Rodgers G, Berndt M, Fonteno M, Gilreath J
J Blood Med
. 2023 Mar;
14:209-211.
PMID: 36891167
We describe a case of refractory thrombotic thrombocytopenic purpura (7 lines of therapy) in which caplacizumab was used over a 6-month period as rescue therapy. Caplacizumab maintained the patient in...
8.
Roberts J, von Drygalski A, Zhou J, Rodgers G, Ansteatt K, Tarantino M
J Blood Med
. 2022 Oct;
13:611-618.
PMID: 36303565
Hereditary antithrombin deficiency (ATD) is a rare autosomal dominant condition (estimated prevalence 1:500-1:5000). Most ATD patients have AT activity levels 40-60% of normal. We present treatments for venous thromboembolism (VTE)...
9.
Rodgers G, Ward J, Bray P
Br J Haematol
. 2022 Jul;
198(5):802.
PMID: 35802037
No abstract available.
10.
Auerbach M, Macdougall I, Rodgers G, Deloughery T, Richards T
Am J Hematol
. 2021 Dec;
97(3):250-252.
PMID: 34856013
No abstract available.